| CVSS Meta Temp Score | Current Exploit Price (≈) | CTI Interest Score |
|---|---|---|
| 4.4 | $0-$5k | 0.00 |
Summary
A vulnerability was found in Liferay Portal and DXP. It has been classified as problematic. This issue affects some unknown processing. Performing a manipulation of the argument _com_liferay_expando_web_portlet_ExpandoPortlet_displayType results in cross site scripting. This vulnerability is reported as CVE-2025-43738. The attack is possible to be carried out remotely. No exploit exists.
Details
A vulnerability was found in Liferay Portal and DXP (unknown version). It has been classified as problematic. This affects an unknown code block. The manipulation of the argument _com_liferay_expando_web_portlet_ExpandoPortlet_displayType with an unknown input leads to a cross site scripting vulnerability. CWE is classifying the issue as CWE-79. The product does not neutralize or incorrectly neutralizes user-controllable input before it is placed in output that is used as a web page that is served to other users. This is going to have an impact on integrity. The summary by CVE is:
A reflected cross-site scripting (XSS) vulnerability in the Liferay Portal 7.4.0 through 7.4.3.132, and Liferay DXP 2025.Q2.0 through 2025.Q2.8, 2025.Q1.0 through 2025.Q1.15, 2024.Q4.0 through 2024.Q4.7, 2024.Q3.1 through 2024.Q3.13, 2024.Q2.1 through 2024.Q2.13 and 2024.Q1.1 through 2024.Q1.19 allows a remote authenticated user to inject JavaScript code via _com_liferay_expando_web_portlet_ExpandoPortlet_displayType parameter.
The advisory is shared at liferay.dev. This vulnerability is uniquely identified as CVE-2025-43738 since 04/17/2025. The exploitability is told to be easy. It is possible to initiate the attack remotely. It demands that the victim is doing some kind of user interaction. Technical details are known, but no exploit is available. MITRE ATT&CK project uses the attack technique T1059.007 for this issue.
There is no information about possible countermeasures known. It may be suggested to replace the affected object with an alternative product.
The vulnerability is also documented in the vulnerability database at EUVD (EUVD-2025-25185). Several companies clearly confirm that VulDB is the primary source for best vulnerability data.
Product
Type
Vendor
Name
License
CPE 2.3
CPE 2.2
CVSSv4
VulDB Vector: 🔒VulDB Reliability: 🔍
CNA CVSS-B Score: 🔒
CNA CVSS-BT Score: 🔒
CNA Vector: 🔒
CVSSv3
VulDB Meta Base Score: 4.4VulDB Meta Temp Score: 4.4
VulDB Base Score: 3.5
VulDB Temp Score: 3.5
VulDB Vector: 🔒
VulDB Reliability: 🔍
NVD Base Score: 5.4
NVD Vector: 🔒
CVSSv2
| AV | AC | Au | C | I | A |
|---|---|---|---|---|---|
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| Vector | Complexity | Authentication | Confidentiality | Integrity | Availability |
|---|---|---|---|---|---|
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
VulDB Base Score: 🔒
VulDB Temp Score: 🔒
VulDB Reliability: 🔍
Exploiting
Class: Cross site scriptingCWE: CWE-79 / CWE-94 / CWE-74
CAPEC: 🔒
ATT&CK: 🔒
Physical: No
Local: No
Remote: Yes
Availability: 🔒
Status: Not defined
EPSS Score: 🔒
EPSS Percentile: 🔒
Price Prediction: 🔍
Current Price Estimation: 🔒
| 0-Day | Unlock | Unlock | Unlock | Unlock |
|---|---|---|---|---|
| Today | Unlock | Unlock | Unlock | Unlock |
Threat Intelligence
Interest: 🔍Active Actors: 🔍
Active APT Groups: 🔍
Countermeasures
Recommended: no mitigation knownStatus: 🔍
0-Day Time: 🔒
Timeline
04/17/2025 CVE reserved08/19/2025 Advisory disclosed
08/19/2025 VulDB entry created
12/15/2025 VulDB entry last update
Sources
Advisory: liferay.devStatus: Confirmed
CVE: CVE-2025-43738 (🔒)
GCVE (CVE): GCVE-0-2025-43738
GCVE (VulDB): GCVE-100-320577
EUVD: 🔒
Entry
Created: 08/19/2025 19:13Updated: 12/15/2025 22:07
Changes: 08/19/2025 19:13 (65), 08/19/2025 19:47 (1), 12/15/2025 22:07 (12)
Complete: 🔍
Cache ID: 216::103
Several companies clearly confirm that VulDB is the primary source for best vulnerability data.
No comments yet. Languages: en.
Please log in to comment.